全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
- Sohn HJ1, Han DH, Lee DY, Nam DH.Author information 1Department of Ophthalmology, Hongik Hospital, Seoul, KoreaDepartment of Ophthalmology, Gachon University Gil Hospital, Incheon, Korea.AbstractPurpose: To investigate the changes in the aqueous levels of various cytokines after intravitreal triamcinolone or bevacizumab for branch retinal vein occlusion (BRVO). Methods: Twenty-four eyes with macular oedema associated with BRVO and six eyes of six patients undergoing cataract surgery participated in this study. Each patient with BRVO randomly received an intravitreal injection of either 4 mg triamcinolone or 1.25 mg bevacizumab. Aqueous samples were obtained before and 4 weeks after the intravitreal injection in the BRVO group and before surgery in the control group. Aqueous concentrations of 16 cytokines were measured via multiplex bead assay. Results: Prior to the administration of the drugs, aqueous levels of interleukin (IL)-6, IL-8, IL-17 and vascular endothelial growth factor (VEGF) were significantly higher in the BRVO group than in the control group (p = 0.044, p = 0.013, p < 0.001, and p = 0.008, respectively). Between the control group and the BRVO group, no significant differences were noted between pre- and postinjection best-corrected visual acuity (p = 0.60, p = 0.54) and central foveal thickness (p = 0.47, p = 0.82). In the triamcinolone group, levels of IL-6, IL-17, IP-10, platelet-derived growth factor (PDGF)-AA and VEGF were reduced significantly (p = 0.012, p < 0.001, p < 0.001, p = 0.015, and p < 0.001, respectively). But in bevacizumab group, only VEGF was significantly reduced (p < 0.001). Between the IVTA group and the IVBe group, no significant differences in the changes in VEGF levels were noted (p = 0.06). Conclusion: Triamcinolone injection reduces plural inflammatory cytokines in BRVO, while bevacizumab has no influence on other cytokines as selective anti-VEGF therapy. No differences in the therapeutic effect were noted between an inhibition of plural inflammatory cytokines and an inhibition of VEGF only.
- Acta ophthalmologica.Acta Ophthalmol.2014 May;92(3):e217-24. doi: 10.1111/aos.12219. Epub 2013 Jul 26.
- Purpose: To investigate the changes in the aqueous levels of various cytokines after intravitreal triamcinolone or bevacizumab for branch retinal vein occlusion (BRVO). Methods: Twenty-four eyes with macular oedema associated with BRVO and six eyes of six patients undergoing cataract surgery p
- PMID 23889803
- Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
- Yasuda S1, Kachi S, Ueno S, Ushida H, Piao CH, Kondo M, Terasaki H.Author information 1Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, 466-8550, Japan.AbstractPURPOSE: Hemicentral retinal vein occlusion (hCRVO) is a disease related to CRVO but not to branch retinal vein occlusion (BRVO). We reported a significant correlation between aqueous vascular endothelial growth factor (VEGF) levels and the implicit time of 30-Hz flicker electroretinogram (ERG) in CRVO eyes. The purpose of this study was to compare aqueous VEGF levels and ERG components between hCRVO and BRVO eyes.
- Japanese journal of ophthalmology.Jpn J Ophthalmol.2014 May;58(3):232-236. Epub 2014 Mar 26.
- PURPOSE: Hemicentral retinal vein occlusion (hCRVO) is a disease related to CRVO but not to branch retinal vein occlusion (BRVO). We reported a significant correlation between aqueous vascular endothelial growth factor (VEGF) levels and the implicit time of 30-Hz flicker electroretinogram (ERG) in C
- PMID 24668132
- A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO).
- Taylor M1, Serbetci E, Ferreira A, Gairy K, Lewis L, Blouin J, Mitchell P.Author information 1York Health Economics Consortium Ltd, University of York , York , UK.AbstractAbstract Objective: This study compares the cost-effectiveness of intravitreal ranibizumab vs observation and/or laser photocoagulation for treatment of macular edema secondary to retinal vein occlusion in a UK-based model. Methods: A Markov model was constructed using transition probabilities and frequency of adverse events derived using data from the BRAVO, CRUISE, and HORIZON trials. Outcomes associated with treatments and health states were combined to predict overall health costs and outcomes for cohorts treated with each option. Results: In branch retinal vein occlusion, ranibizumab produced a gain of 0.518 quality-adjusted life years at an incremental cost of £8141, compared with laser photocoagulation. The incremental cost-effectiveness ratio was £15,710 per quality-adjusted life year, and the incremental cost per month free from blindness was £658. In central retinal vein occlusion, ranibizumab produced a gain of 0.539 quality-adjusted life years at an incremental cost of £9216, compared with observation only. The incremental cost-effectiveness ratio was £17,103, and the incremental cost per month free from blindness was £423. Conclusions: These incremental cost-effectiveness ratios are below the £20,000-30,000 range typically accepted as a threshold for cost-effectiveness. This suggests that ranibizumab may be regarded as a cost-effective therapy for patients with macular edema secondary to retinal vein occlusion, relative to grid laser photocoagulation (for BRVO) and observation (for CRVO). Limitations include sparse data for utilities associated with the severity of visual impairment in the WSE in patients with RVO. A lack of direct comparative evidence between ranibizumab and the dexamethasone intravitreal implant for the treatment of BRVO and CRVO and the infeasibility of an indirect comparison due to significant heterogeneity in trial designs prevented the inclusion of this treatment as a comparator in the Markov model.
- Journal of medical economics.J Med Econ.2014 Apr 22. [Epub ahead of print]
- Abstract Objective: This study compares the cost-effectiveness of intravitreal ranibizumab vs observation and/or laser photocoagulation for treatment of macular edema secondary to retinal vein occlusion in a UK-based model. Methods: A Markov model was constructed using transition probabilities and f
- PMID 24673384
- BRVO,CRVOのマネージメント (特集 網膜血管病の病態とマネージメント)
- Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion.
- Ogino Ken,Tsujikawa Akitaka,Murakami Tomoaki,Muraoka Yuki,Kurashige Yumiko,Yoshimura Nagahisa
- Clinical ophthalmology (Auckland, N.Z.) 5, 1031-1036, 2011-07
- … Methods: This retrospective study consisted of 19 eyes with branch retinal vein occlusion (BRVO) and nine eyes with central retinal vein occlusion (CRVO), which were treated with grid photocoagulation combined with IVB for recurrent macular edema after previous IVBs. … Compared with initial values, final foveal thickness was reduced significantly in both BRVO and CRVO groups (P < … 0.001), but improvement in VA was significant only for eyes with BRVO (P = 0.012). …
- NAID 120003338838
- 2006年11月2日 ... 網膜静脈分枝閉塞症(BRVO)について－. 【概論】 網膜静脈分枝閉塞症 branch retinal vein occlusion,BRVOとは、網膜静脈の分岐が閉塞を来たし、網膜に出血を来たす 疾患である。上耳側静脈域に好発する。網膜中心静脈閉塞症より頻度 ...
- retinal vein occlusion, obstruction of the retinal vein
- 年齢、高血圧、糖尿病、喫煙、肥満、凝固亢進状態(factor V Leiden, activated protein C resistance)、緑内障、網膜細血管異常(retinal arteriolar abnormality)
||静脈うっ滞網膜症 venous stasis retinopathy：静脈拡張、出血など静脈閉塞のみを主症状とする。
出血性網膜症 hemorrhagic retinopathy：高度の血管床閉塞など動脈の循環障害を併発
- 1. [charged] Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis - uptodate 
- branch retinal vein occlusion BRVO